JP2003300887A - Mixture having antiallergic effect and food product containing the same - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a food product dealing with I-type allergy by including a mixture of fucoidan powder and powder of Kuchocha extract (a tea drink product obtained by decocting the whole dried grass of Corydalis bungeana Turcz belonging to the family Papaveraceae). <P>SOLUTION: The food product contains the mixture of fucoidan powder and Kuchocha extract powder. Prior to develop the food product, the efficacy of the mixture is tested as follows. A test sample is prepared by formulating fucoidan powder and Kuchocha powder in the weight ratio of (1:1). In a mouse administration test, assuming that the IgE production for a control group is 100, a pre-administration group and a post-administration group give IgE productions of 77.1 and 51.8, respectively, indicating suppression of the IgE production. The PCA (passive cutaneous anaphylavis) reaction suppression rate for the control group is also lowered. In a human volunteer test, there are no aggravations of the pollinoses of the eyes, nose and throat, the efficacy rates for the symptoms for the eyes, nose and throat are 85.3%, 90.6% and 83.6%, respectively. There are many subjects who are conscious of ameliorating the symptoms within about one hour for the eyes and nose, thus demonstrating the quick efficacy of the tested samples. <P>COPYRIGHT: (C)2004,JPO

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD [0001] The present invention relates to an antiallergic mixture, and in particular, an antiallergic mixture of a seaweed-derived fucoidan or a fucoidan-like substance having an IgE production inhibitory action and a Kending tea extract involved in inhibiting histamine release. Working mixture.

[0002]

2. Description of the Related Art In recent years, the number of type I allergic patients represented by hay fever, specific foods or allergy to house dust has been rapidly increasing. Therefore, various studies have been made on type I allergy, and various drugs and foods have been developed. One of them is I on the surface of mast cells and basophils.
Various antagonists that block the gE receptor have been developed and are already on the market as pharmaceuticals. In addition, since intracellular proteases (mainly serine proteases) and hyaluronidase are involved in the release of chemical mediators such as histamine, these inhibitors have been reported to be effective (Kawagoe, S., (1994)
Fragrance J. 8: 81-86).

Since ancient times, it has been empirically reported in Japan that various plants such as shiso leaves, loquat leaves, dokudami and aloe have anti-inflammatory and anti-allergic effects. It is beginning to become clear that the anti-inflammatory and anti-allergic effects are due to the inhibition of hyaluronidase and cyclooxygenase, which are inflammatory substances, and active attempts are being made to use these inhibitors as anti-allergic substances (JP-A-07-10765). Japanese Patent Laid-Open No. 06-06
No. 192114), anti-type I allergic foods containing these anti-allergic substances as main components are commercially available.

[0004]

However, many anti-type I allergic foods and medicines known to date have insufficient effects, and many have side effects such as drowsiness and thirst. .

By the way, the fucoidan derived from seaweed has strong I
It is already known to have a gE production inhibitory action (Tanihisa, T., Oishi, K., (1998) New Food Industry.
40 (10): 15/20). However, since fucoidan has poor immediate effect, it is necessary to continue to take it in advance.

On the other hand, Kitchingcha is a plant (scientific name: Ilex Iatifolia Thunb) which has been used in China since ancient times because it has an action of improving hypertension and hyperlipidemia. When the histamine release inhibitory effect of this bitter tea extract was examined, among the conventionally known plant-derived ones,
The present inventor has found that it shows a very high inhibition of histamine release.

Based on this finding, the present inventor has prepared a type I allergenic substance by blending fucoidan, which has a persistent IgE production inhibitory action, and a dying tea extract involved in the inhibition of histamine release, which exhibits immediate effect. The present invention has led to the development of a type I allergy-friendly diet that reduces the effects of the above and causes an immune-tolerant state.

An object of the present invention is to provide a mixture containing fucoidan and bitter tea extract having an antiallergic effect, and an antiallergic food containing the mixture.

[0009]

The antiallergic mixture of the present invention for solving the above-mentioned problems comprises a seaweed-derived fucoidan powder or a fucoidan-like substance powder having an IgE production inhibitory action, and a bite having a histamine release inhibiting action. It is a blend of Dingcha extract powder.

Further, the antiallergic food of the present invention is
It is a food containing the above-mentioned anti-allergic action mixture.

In the present invention, the effects of type I allergic agents are reduced by blending fucoidan, which has a persistent IgE production inhibitory action, and a bitter tea extract, which has a fast-acting histamine release inhibitory action, while reducing the effects of type I allergenic agents. Produce a tolerance-like state.

[0012]

BEST MODE FOR CARRYING OUT THE INVENTION Embodiments of the present invention will be described below with reference to the drawings.

FIG. 1 is a conceptual diagram for explaining the components of the antiallergic mixture and the antiallergic food of the present invention.

The antiallergic action mixture 3 of the present invention is a mixture of the powder of Kending tea extract 1 having a fast-acting histamine release inhibiting action and the fucoidan powder 2 having a persistent IgE production inhibiting action. Bitter green tea extract powder 1
It includes ursolic acid, β-amylin, lupeol, taraxerol, ubaol, β-sitosterol, proteins, essential amino acids, vitamins and minerals. The fucoidan powder 2 is a plant fiber contained in seaweed such as kelp, seaweed, and mozuku, and is a sulfated polysaccharide in which a sulfate group is bonded to fucose (saccharide). Among these, fucoidan containing glucuronic acid or fucoidan consisting only of sulfated fucose is preferable as a component of the antiallergic mixture 3. Bitter tea extract powder 1 and fucoidan powder 2
Can be obtained, for example, by hot water extraction. The fucoidan powder 2 can also be obtained by weak alkali extraction.

The blending ratio of the powder of menthol tea extract 1 and the powder of fucoidan 2 in the mixture 3 for antiallergic action is preferably 1: 1 by weight. However, when the immediate effect histamine release inhibitory effect is emphasized, the ratio of the menthol tea leaf extract powder 1 is increased, and when the sustained IgE production inhibitory effect is emphasized, the ratio of the fucoidan powder 2 is increased.

Further, the antiallergic food 5 of the present invention
Is a mixture of the antiallergic action mixture 3 and the food 4 such as confectionery and beverage. In order to produce the antiallergic action food 5, not only the method of mixing the antiallergic action mixture 3 and the food 4 but also, for example, the menthol tea leaf extract powder 1
The fucoidan powder 2 and the food 4 may be mixed at the same time. The blending ratio of the antiallergic mixture 3 in the antiallergic food 5 is preferably 1% or more and 99% or less in terms of weight ratio, and the blending ratio depends on the strength of the effect, whether it is for children or adults, etc. decide.

[0017]

Example In this example, a test substance was a mixture in which the powder 1 of menthol tea extract and the powder 2 of fucoidan were mixed at a weight ratio of 1: 1. In the present example, the bitter green tea extract powder 1 is hot water extracted from the green leaf of bitter green tea.
Specifically, chop the bitter green tea leaves at 80 ℃ ~ 100 ℃ 3
It is a dry powder extracted by boiling in hot water for 0 to 60 minutes, evaporating water from the boiling liquid, and removing leaves after boiling. The temperature / time is not limited to the above range, and hot water extraction may be performed under pressure. Further, the fucoidan powder 2 is obtained by extracting a mild alkali from Mozuku. Specifically, Mozuku, 50 ℃ ~ 1
00 ° C (more preferably 80 ° C to 95 ° C) for 10 minutes to 12
During 0 minutes (more preferably 30 to 60 minutes), in a weak alkaline liquid containing an alkaline reagent such as NaOH (for example, pH 7.1).
To 9.0 (more preferably pH 7.5 to 8.0) to remove mozuku after boiling and electrodialysis to remove Na.
It is a dry powder extracted by removing ions and OH ions.

Next, the results of confirming the antiallergic action by orally ingesting this test substance in mice will be explained.

In this test, 10 mg / kg (body weight) /
The BALB / c mice were orally ingested on the 4th day of the day. After one week, a mixture of 10 μg of β-lactoglobulin and 1 mg of alum was intraperitoneally administered to a mouse for immunization. After that, the test substance was orally given continuously to the preadministration group for 3 consecutive days so that the test substance might be 10 mg / kg (body weight) / day. On the other hand, the post-administration group was immunized with β-lactoglobulin again, and immediately thereafter, the test substance was orally ingested at 10 mg / kg (body weight) / day for 3 consecutive days. Blood samples were collected from the pre-administration group and the post-administration group after three consecutive days of oral intake, serum was obtained by a standard method, and IgE production was examined by an ELISA method, and anti-type I allergic effect was examined by a PCA test. It was

The control group was given the same amount of beet extract in the same period.

FIG. 2 is a table showing the amount of IgE produced and the results of the PCA test.

As shown in the table, IgE of the control group
When the production amount was set to 100, it was 77.1 in the pre-administration group and 51.8 in the post-administration group, and the IgE production amount was suppressed in both the pre-administration group and the post-administration group. In addition, when the PCA reaction inhibitory rate of the control group was 100%, it was 99% in the pre-administration group and 75% in the post-administration group, indicating that the PCA response inhibitory rate was decreased in both the pre-administration group and the post-administration group. It was

Next, the results of confirming the antiallergic action by orally ingesting the above-mentioned test substance in humans will be described.

The subject was a hay fever patient by self-diagnosis 14
People (7 men, 7 women, ages 21-63), 1 healthy person
There are 8 people (9 men, 9 women, age 25-65).
The administration period is from February to April of 200 and from 2 to 4 of 2001.
I went twice a month. No restrictions were placed on the lifestyle, including eating habits, except that the test substance was ingested twice daily in the morning and evening. The test substance was ingested by the test subjects for about 2 months. The dose was 10 mg / kg (body weight) / day, as in the case of the mouse experiment described above. After ingesting this test substance for about 2 months, a questionnaire survey was conducted for each symptom of eye, nose and throat.

The table shown in FIG. 3 is a table showing the ratio (%) of persons who answered that the result of ingestion was effective, moderately effective, or ineffective.

As shown in the table, the effective rates for each of the eye, nose, and throat symptoms were 85.3%, 90.6%, and 83.6%, respectively. And they are 94.1%, 98.2%, and 91.
Reached 2%. In addition, many volunteers were able to realize improvement symptoms for nose and eyes in about 1 hour, and immediate effect was observed. The proportion of subjects who responded that no effect was observed for each of the eye, nose, and throat symptoms was
Only 5.9%, 1.8%, and 8.8%. None of the subjects answered that their symptoms had worsened.

Moreover, no physical change could be observed in the healthy subjects who were investigated at the same time.

As described above, oral ingestion of the antiallergic substance of the present invention improved the eye, nose, and throat symptoms of hay fever in most people.

The present invention is not limited to the embodiment described above.

For example, instead of fucoidan derived from seaweed,
A seaweed-derived fucoidan-like substance (a substance in which a sulfate group is bound to a substance in which fucose is linked to other sugars (xylose, mannose, galactose)) may be used.

The antiallergic substance of the present invention may be granules or tablets (sugar-coated tablets, etc.). Further, an antiallergic substance may be dissolved in syrup or the like.

[0032]

INDUSTRIAL APPLICABILITY According to the present invention, a mixture having an anti-allergic substance action, which is a mixture of fucoidan derived from seaweed and bitter tea extract, can be obtained. This anti-allergic action mixture is used as powder, granules, tablets, syrups and the like. Moreover, the antiallergic mixture is used by being mixed with food. By ingesting this mixture or a food containing the mixture, the production of IgE and the release of histamine are suppressed.
Type allergy symptoms are improved. In particular, type I allergy such as hay fever is suppressed.

[Brief description of drawings]

FIG. 1 is a conceptual diagram for explaining components of an antiallergic mixture of the present invention and foods containing the same.

FIG. 2 is a table showing the effects of this test substance in a type I allergy animal model.

FIG. 3 is a table showing an anti-hay fever effect in a human volunteer test.

[Explanation of symbols]

1 Bitter green tea extract powder 2 fucoidan powder 3 Antiallergic mixture 4 food 5 Antiallergic foods

Continuation of front page (51) Int.Cl. ⁷ Identification code FI theme code (reference) A61P 43/00 111 A61P 43/00 111 113 113 113 123 123 C08B 37/00 C08B 37/00 Q (72) Inventor Ritsuko Fujioka 9-25 Ebiyamacho, Saiki-ku, Hiroshima City, Hiroshima Prefecture (Reference) 4B018 LE03 MD33 MD61 MD67 ME07 MF01 MF06 4C086 AA01 AA02 EA26 MA02 MA04 MA52 NA05 NA14 ZA33 ZA34 ZB13 ZC41 ZC45 4C088 AB12 AC05 BA09 CA02 CA34 ZA33 CA34 ZB33 CA34 ZB45 CA25 ZB33 CA34 ZB45 CZ ZA33 ZB45 C33 ZB33 C33 ZB45 C33 ZB33 C33 ZB45 C33 ZB <b> 33 C33 ZB <b> 44 4C090 AA09 BA64 BB10 BB11 BB13 BB14 BB22 BB63 BC06 CA10 CA33 DA23 DA27

Claims (6)

[Claims] 1. An anti-allergic action mixture comprising a fucoidan powder derived from seaweed or a fucoidan-like substance powder having an IgE production inhibitory action, and a bitter tea extract powder having a histamine release inhibiting action. 2. A seaweed-derived fucoidan powder or fucoidan-like substance powder having an IgE production inhibitory action and a Kending tea extract powder having a histamine release inhibiting action are used in a weight ratio of 1.
The anti-allergic action mixture according to claim 1, which is mixed in a ratio of 1. 3. The anti-allergic action mixture according to claim 1, wherein the powder of the bitter green tea extract is a dry powder extracted from the leaves of the bitter green tea by hot water extraction. 4. The anti-allergic action mixture according to claim 1, wherein the fucoidan powder derived from seaweed or the fucoidan-like substance powder is a dry powder extracted from seaweed by mild alkali extraction. 5. An anti-allergic action mixture containing a fucoidan powder or a fucoidan-like substance powder derived from seaweed having an IgE production inhibitory action and a bitter tea extract powder having a histamine release inhibiting action is contained. Antiallergic food. 6. The antiallergic food according to claim 5, wherein the antiallergic mixture is contained in a range of 1% to 99% by weight.